hepatocellular carcinoma
First Agent Ever Demonstrates Significant Benefit in Liver Cancer
NEXAVAR(R) Proven to Extend Overall Survival by 44 Per Cent
TORONTO, June 4 /CNW/ - Results from a new global study have shown that
NEXAVAR(R) (sorafenib tablets) is proven to extend overall survival in
patients with hepatocellular carcinoma (HCC), or primary liver cancer versus
those taking placebo by 44 per cent. These findings were released today at the
43rd annual meeting of the American Society of Clinical Oncology (ASCO) in
Chicago, Illinois....
http://www.newswire.ca/en/releases/archive/June2007/04/c7795.html
Peace,
Anne
Comments
-
http://money.cnn.com/news/newsfeeds/articles/prnewswire/LNW50111072007-1.htm
Progen Pharmaceuticals Outlines Preliminary Phase 3 Clinical Trial Design - Patient Enrollment Planned for Second Half of 2007-
-snip-
In April, Progen announced the final stage 1 results of its Phase 2 trial of PI-88 in patients who had previously undergone surgical removal of liver cancer. The 48 week data demonstrated that 160 mg of PI-88 showed an improvement in disease-free rate of 25 percent and prolonged the time to tumour recurrence (disease free survival) from 27 to 48 weeks, or by 78 percent, building on the 30-week results previously announced in December 2006. On the strength of these data, Progen announced its intention to plan a multi-national Phase 3 trial of PI-88 at a dose of 160mg/day.
-snip-
Peace,
Anne0 -
liver cancerannes449 said:http://money.cnn.com/news/newsfeeds/articles/prnewswire/LNW50111072007-1.htm
Progen Pharmaceuticals Outlines Preliminary Phase 3 Clinical Trial Design - Patient Enrollment Planned for Second Half of 2007-
-snip-
In April, Progen announced the final stage 1 results of its Phase 2 trial of PI-88 in patients who had previously undergone surgical removal of liver cancer. The 48 week data demonstrated that 160 mg of PI-88 showed an improvement in disease-free rate of 25 percent and prolonged the time to tumour recurrence (disease free survival) from 27 to 48 weeks, or by 78 percent, building on the 30-week results previously announced in December 2006. On the strength of these data, Progen announced its intention to plan a multi-national Phase 3 trial of PI-88 at a dose of 160mg/day.
-snip-
Peace,
Anne
Anne, I lost my husband on Feb. 4th, 2009 just 4 weeks ago. He had hep.C & cirrohis. The drs. found a mass back in the summer while he was in the hospital but said it was not cancer. We were waiting for a transplant but on Jan 26, 2009 he had a C-scan & the drs. said it had grown from 1 centemiter to over 5 & was the most aggressive cancer he had ever seen. He lived for 9 days & passed away with liver failure. We are blessed that he left before the cancer spread over his whole body & he was not in terrible pain. Love, Renee0 -
I hope you now know how common this iskoozy said:liver cancer
Anne, I lost my husband on Feb. 4th, 2009 just 4 weeks ago. He had hep.C & cirrohis. The drs. found a mass back in the summer while he was in the hospital but said it was not cancer. We were waiting for a transplant but on Jan 26, 2009 he had a C-scan & the drs. said it had grown from 1 centemiter to over 5 & was the most aggressive cancer he had ever seen. He lived for 9 days & passed away with liver failure. We are blessed that he left before the cancer spread over his whole body & he was not in terrible pain. Love, Renee
Likely your husband had hepC for many many years.
Tell EVERYONE you come into contct with to get tested.
more here: www.hcop.org/blog
support hepC PREVENTION. Death and transplants can be prevented and more organs made available more timely.
not a drug user's disease.
If he was a veteran, you may have $$$ coming to you as many vets were infected from vaccine guns.0
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 121.8K Cancer specific
- 2.8K Anal Cancer
- 446 Bladder Cancer
- 309 Bone Cancers
- 1.6K Brain Cancer
- 28.5K Breast Cancer
- 397 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13K Head and Neck Cancer
- 6.4K Kidney Cancer
- 671 Leukemia
- 792 Liver Cancer
- 4.1K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 237 Multiple Myeloma
- 7.1K Ovarian Cancer
- 61 Pancreatic Cancer
- 487 Peritoneal Cancer
- 5.5K Prostate Cancer
- 1.2K Rare and Other Cancers
- 539 Sarcoma
- 730 Skin Cancer
- 653 Stomach Cancer
- 191 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.8K Uterine/Endometrial Cancer
- 6.3K Lifestyle Discussion Boards